Abstract
The FDA approved the tyrosine kinase inhibitor neratinib for extended adjuvant treatment of early-stage HER2-positive breast cancer. The decision adds another treatment option to help prevent recurrence, but its relatively small potential benefit must be weighed against the risk of serious side effects.
©2017 American Association for Cancer Research.
MeSH terms
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Drug Approval
-
Female
-
Humans
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / genetics
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinolines / therapeutic use*
-
Receptor, ErbB-2 / genetics
Substances
-
Protein Kinase Inhibitors
-
Quinolines
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
neratinib